MAZE · Maze Therapeutics, Inc. · Executive Compensation
$31.37
-1.06 (-3.27%)
At close · Nov 20
Return incl. dividend (before tax)
Market Cap
$1.72B
Shares
54.68M
Volume · Nov 20
818.95K
Avg daily vol (3M)
730.21K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Hervé Hoppenot | Class III director | Appointed | 2026-08-17 |
| Hervé Hoppenot | Class II director | Resigned | 2026-08-17 |
| Nancy C. Andrews, M.D., Ph.D. | Class II director | Appointed | 2026-08-17 |
| Nancy C. Andrews, M.D., Ph.D. | Class III director | Resigned | 2026-08-17 |
| Sophie Kornowski, Pharm.D. | Class I director | Appointed | 2026-08-17 |
| Paula A. Johnson, M.D., M.P.H. | Class III director | Appointed | 2026-08-17 |
|
Amy Bachrodt
“Ms. Bachrodt’s resignation was not as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices or on any matter relating to the Company’s financial reporting.”
|
Senior Vice President, Finance | Resigned | 2026-05-22 |
| Neil Kumar | Class I director | Appointed | 2026-03-25 |
| Hervé Hoppenot | Class II director | Appointed | 2025-10-06 |
| Hervé Hoppenot | Chairman of the Board | Appointed | 2025-10-06 |
| Misbah Tahir | Chief Financial Officer and "principal financial officer" | Appointed | 2025-09-02 |
Leadership
- Jason Coloma CEO, Board Member
- Hervé Hoppenot Chairman, Board Member
- Misbah Tahir CFO
- Courtney Phillips General Counsel
- Charles Homcy Board Member
- Continuing Directors Board Member
- Daniel Spiegelman Board Member
- Jonathan Lim Board Member
- Nancy C. Andrews, M.D., Ph.D. Board Member
- Neil Kumar Board Member
- Paula A. Johnson Board Member
- Paula A. Johnson, M.D., M.P.H. Board Member
- Richard Scheller Board Member
- Sophie Kornowski Board Member
- Sophie Kornowski, Pharm.D. Board Member
Key facts
CIK
1842295
CUSIP
578784100
13F (30d)
158 filings
153 filers
Visit website
Investor relations